P. V. Afanasyeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
P. V. Afanasyeva has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anna Zlotina
Almazov National Medical Research Center
1 shared publication - Ekaterina A. Elpaeva
Almazov National Medical Research Center, Institute of Molecular Biology and Genetics, St. Petersburg, Russia
1 shared publication - Ekaterina G. Nikitina
Almazov National Medical Research Center, Institute of Molecular Biology and Genetics, St. Petersburg, Russia
1 shared publication - Elena V. Shmendel
Lomonosov Institute of Fine Chemical Technologies, MIREA – Russian Technological University, Moscow, Russia
1 shared publication - M. D. Kerbitskaya
Lomonosov Institute of Fine Chemical Technologies, MIREA – Russian Technological University, Moscow, Russia
1 shared publication - Marina A. Shuklina
Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia
1 shared publication
Latest Publications
- 30 October 2026
- Published by Pleiades Publishing Ltd in Cell and Tissue Biology
- Vol. 20 (S4) , S535-S554
Optimal Exosome–Liposome Ratio in Hybrid Particles for Efficient Delivery of mRNA and siRNA to Human Cardiac Cells
Objective: Cardiovascular disease remains the leading global cause of mortality, driving an urgent need for novel therapeutics capable of addressing both acute and chronic pathologies. RNA-based strategies—particularly RNA interference and mRNA-based protein replacement—hold considerable promise in this context. However, their clinical translation is critically hindered by the lack of efficient delivery systems capable of transfecting hard-to-transfect primary cardiac cells, which are essential for preclinical evaluation. In this study, we optimized a hybrid delivery platform combining human serum-derived exosomes with 2X3-DOPE cationic liposomes for the transport of both small interfering RNA (siRNA) and messenger RNA (mRNA) into primary human cardiac cells. Methods: Chemically synthesized siRNA and eGFP-encoding mRNA were used as cargo. Delivery efficiency was assessed via target gene knockdown (qPCR) for siRNA and eGFP expression (flow cytometry) for mRNA, using both CMCs and iPSC-derived cardiomyocytes. We systematically varied the exosome-to-liposome molar ratio and assembly order to identify optimal formulation conditions. Results and Discussion: For siRNA, the highest silencing activity was achieved at a 1/0.5 ratio, with particles formed by pre-assembling exosomes and liposomes prior to siRNA loading. In contrast, mRNA delivery was most effective at a 1/0.2 ratio, requiring initial complexation of liposomes with mRNA before exosome addition. These conditions were validated in iPSC-cardiomyocytes. Conclusions: Collectively, our findings establish a robust formulation framework for exosome-liposome hybrids tailored to cardiac cell types. The optimized platforms will now be evaluated in vivo following intravenous and intrapericardial administration in murine models, supporting the future development of RNA therapeutics for inherited and acquired myocardial disorders.
- 30 October 2026
- Published by Pleiades Publishing Ltd in Cell and Tissue Biology
- Vol. 20 (S4) , S535-S554
Optimal Exosome–Liposome Ratio in Hybrid Particles for Efficient Delivery of mRNA and siRNA to Human Cardiac Cells
Objective: Cardiovascular disease remains the leading global cause of mortality, driving an urgent need for novel therapeutics capable of addressing both acute and chronic pathologies. RNA-based strategies—particularly RNA interference and mRNA-based protein replacement—hold considerable promise in this context. However, their clinical translation is critically hindered by the lack of efficient delivery systems capable of transfecting hard-to-transfect primary cardiac cells, which are essential for preclinical evaluation. In this study, we optimized a hybrid delivery platform combining human serum-derived exosomes with 2X3-DOPE cationic liposomes for the transport of both small interfering RNA (siRNA) and messenger RNA (mRNA) into primary human cardiac cells. Methods: Chemically synthesized siRNA and eGFP-encoding mRNA were used as cargo. Delivery efficiency was assessed via target gene knockdown (qPCR) for siRNA and eGFP expression (flow cytometry) for mRNA, using both CMCs and iPSC-derived cardiomyocytes. We systematically varied the exosome-to-liposome molar ratio and assembly order to identify optimal formulation conditions. Results and Discussion: For siRNA, the highest silencing activity was achieved at a 1/0.5 ratio, with particles formed by pre-assembling exosomes and liposomes prior to siRNA loading. In contrast, mRNA delivery was most effective at a 1/0.2 ratio, requiring initial complexation of liposomes with mRNA before exosome addition. These conditions were validated in iPSC-cardiomyocytes. Conclusions: Collectively, our findings establish a robust formulation framework for exosome-liposome hybrids tailored to cardiac cell types. The optimized platforms will now be evaluated in vivo following intravenous and intrapericardial administration in murine models, supporting the future development of RNA therapeutics for inherited and acquired myocardial disorders.